250 related articles for article (PubMed ID: 18007201)
21. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment.
Kells AP; Henry RA; Connor B
Gene Ther; 2008 Jul; 15(13):966-77. PubMed ID: 18323792
[TBL] [Abstract][Full Text] [Related]
22. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
23. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
[TBL] [Abstract][Full Text] [Related]
24. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
25. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
Popovic N; Maingay M; Kirik D; Brundin P
Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
[TBL] [Abstract][Full Text] [Related]
26. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
Klapstein GJ; Levine MS
J Neurophysiol; 2005 Feb; 93(2):758-65. PubMed ID: 15371492
[TBL] [Abstract][Full Text] [Related]
27. Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice.
Luellen BA; Bianco LE; Schneider LM; Andrews AM
Genes Brain Behav; 2007 Jul; 6(5):482-90. PubMed ID: 17156118
[TBL] [Abstract][Full Text] [Related]
28. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
Nicniocaill B; Haraldsson B; Hansson O; O'Connor WT; Brundin P
Eur J Neurosci; 2001 Jan; 13(1):206-10. PubMed ID: 11135020
[TBL] [Abstract][Full Text] [Related]
29. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
Bolivar VJ; Manley K; Messer A
Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
[TBL] [Abstract][Full Text] [Related]
30. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
Ariano MA; Cepeda C; Calvert CR; Flores-Hernández J; Hernández-Echeagaray E; Klapstein GJ; Chandler SH; Aronin N; DiFiglia M; Levine MS
J Neurophysiol; 2005 May; 93(5):2565-74. PubMed ID: 15625098
[TBL] [Abstract][Full Text] [Related]
31. Extracellular ascorbate modulates cortically evoked glutamate dynamics in rat striatum.
Rebec GV; Witowski SR; Sandstrom MI; Rostand RD; Kennedy RT
Neurosci Lett; 2005 Apr; 378(3):166-70. PubMed ID: 15781152
[TBL] [Abstract][Full Text] [Related]
32. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
33. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
[TBL] [Abstract][Full Text] [Related]
34. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease.
Simmons DA; Casale M; Alcon B; Pham N; Narayan N; Lynch G
Glia; 2007 Aug; 55(10):1074-84. PubMed ID: 17551926
[TBL] [Abstract][Full Text] [Related]
35. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
36. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
André VM; Cepeda C; Venegas A; Gomez Y; Levine MS
J Neurophysiol; 2006 Apr; 95(4):2108-19. PubMed ID: 16381805
[TBL] [Abstract][Full Text] [Related]
37. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
[TBL] [Abstract][Full Text] [Related]
38. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
[TBL] [Abstract][Full Text] [Related]
39. Striatal transplantation in a transgenic mouse model of Huntington's disease.
Dunnett SB; Carter RJ; Watts C; Torres EM; Mahal A; Mangiarini L; Bates G; Morton AJ
Exp Neurol; 1998 Nov; 154(1):31-40. PubMed ID: 9875265
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
